title: Early cytokine modulation after the rapid induction phase of sublingual immunotherapy with mite monomeric allergoids.
abstract: The influence of different treatment schedules of sublingual immunotherapy (SLIT) in activating IL-10-producing T-cells, crucial in inducing allergen-specific tolerance, is not completely understood. The present work was designed to evaluate allergen driven interleukin release by mononuclear cells in the early phase of SLIT, after application of different induction schemes. Twenty mite-allergic patients were enrolled, 10 (group A) treated with a traditional 98 day induction scheme and 10 (group B) with a 16 day scheme with monomeric allergoid vaccine. At the end of the induction phase, the cumulative doses taken by group A and group B patients were equivalent to 50.5 and 50.3 microg of mite group 1 allergens, respectively. The release of Th1-, Th2- and Treg-related interleukins was assessed in culture supernatants of 5 microg/ml Der-p1-stimulated mononuclear cells, isolated before and after the induction phases. No relevant treatment-related side effects were observed. Interleukin release was similar in the two groups at the enrolment. Non-stimulated and Der p 1 stimulated release of studied cytokines was similar in the two groups at enrolment. Der p 1 stimulation significantly increased IL-10 release (p<0.0002) after treatment in group B patients, and this effect was higher (p=0.05) compared to group A patients. Furthermore, at the end of SLIT induction TNF-alpha, IL-4 and IFN-gamma production were reduced in group B patients (p<0.05, p=0.062 and p=0.060, respectively). The rapid induction scheme of sublingual immunotherapy induces an early immune suppression more effectively than the slower one. The rapid induction scheme should be the preferential way to start sublingual immunotherapy, particularly when monomeric allergoids are utilized.
authors.affiliation: Allergy Related Disease Unit, G. d'Annunzio University Foundation, Chieti, Italy. m.digioacchino@unich.it
authors.forename: M
authors.initials: M
authors.lastname: Di Gioacchino
authors.forename: A
authors.initials: A
authors.lastname: Perrone
authors.forename: C
authors.initials: C
authors.lastname: Petrarca
authors.forename: F
authors.initials: F
authors.lastname: Di Claudio
authors.forename: G
authors.initials: G
authors.lastname: Mistrello
authors.forename: P
authors.initials: P
authors.lastname: Falagiani
authors.forename: V
authors.initials: V
authors.lastname: Dadorante
authors.forename: N
authors.initials: N
authors.lastname: Verna
authors.forename: M
authors.initials: M
authors.lastname: Braga
authors.forename: E
authors.initials: E
authors.lastname: Ballone
authors.forename: E
authors.initials: E
authors.lastname: Cavallucci
mesh_terms: D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage*; D000818:Animals; D016207:Cytokines / Q000378:metabolism*; D003888:Desensitization, Immunologic; D006801:Humans; D008925:Mites / Q000276:immunology*
chemical_list: D000485:Allergens; D016207:Cytokines